Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors
, , , , , , , , , , oraz
27 lut 2025
O artykule
Kategoria artykułu: research article
Data publikacji: 27 lut 2025
Zakres stron: 100 - 109
Otrzymano: 23 sty 2025
Przyjęty: 04 lut 2025
DOI: https://doi.org/10.2478/raon-2025-0017
Słowa kluczowe
© 2025 Tim Wilke et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.

FIGURE 2.

Response to percutaneous electrochemotherapy (pECT) treatment in the 2 groups
RESPONSE | i.v. pECT (N = 21) | i.a. pECT (N = 31) | P value | P value | ||
---|---|---|---|---|---|---|
N | % | N | % | Overall distribution | CR |
|
13 | 61.9% | 25 | 80.6% | 0.3454 | 0.1349 | |
5 | 23.8% | 4 | 12.9% | |||
1 | 4.8% | 0 | 0.0% | |||
0 | 0.0% | 1 | 3.2% | |||
2 | 9.5% | 1 | 3.2% |
Descriptive characteristics of the patients in the 2 groups
PATIENTS | i.v. pECT (N = 18) | i.a. pECT (n = 26) | P value | ||
---|---|---|---|---|---|
N | % | N | % | ||
|
8 | 44% | 15 | 58% | 0.5406 |
|
10 | 56% | 11 | 42% | |
|
7 | 39% | 10 | 38% | 0.4620 |
|
4 | 22% | 4 | 15% | |
|
2 | 11% | 2 | 8% | |
|
0 | 0% | 3 | 12% | |
|
2 | 11% | 0 | 0% | |
|
1 | 6% | 2 | 8% | |
|
1 | 6% | 0 | 0% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
1 | 6% | 0 | 0% | |
Synchronous | 8 | 44% | 16 | 62% | 0.5343 |
Metachronous | 8 | 44% | 8 | 31% | |
No | 2 | 11% | 2 | 7% | |
None | 9 | 50% | 17 | 65% | 0.3613 |
Yes | 9 | 50% | 9 | 35% | |
Lung | 3 | 17% | 3 | 12% | 0.6025 |
Bone | 1 | 6% | 2 | 8% | |
Kidney | 1 | 6% | 1 | 4% | |
Lung + bone + brain | 1 | 6% | 0 | 0% | |
Bone + peritoneum | 1 | 6% | 0 | 0% | |
Pleural + bone | 1 | 6% | 0 | 0% | |
Retroperineal | 1 | 6% | 0 | 0% | |
Adrenal gland | 0 | 0% | 1 | 4% | |
Lymphnode | 0 | 0% | 1 | 4% | |
Bone + lymphnode | 0 | 0% | 1 | 4% | |
Systemic therapy | 16 | 89% | 26 | 100% | 0.1617 |
Liver surgery | 4 | 22% | 12 | 46% | 0.1251 |
Local treatments | 11 | 61% | 8 | 31% | 0.0657 |
TACE | 8 | 43% | 4 | 15% | 0.1529 |
TACE+RFA | 1 | 6% | 0 | 0% | |
TACE+CP | 1 | 6% | 0 | 0% | |
TACE/MWA/CRYOTH | 0 | 0% | 2 | 8% | |
CRYOTH | 1 | 6% | 0 | 0% | |
IBT | 0 | 0% | 2 | 8% | |
Cardiac diseases | 6 | 33% | 7 | 27% | 0.7422 |
Pulmonary diseases | 3 | 17% | 7 | 27% | 0.4889 |
Liver diseases | 9 | 50% | 0 | 0% | <0.0001 |
1 | 15 | 83% | 21 | 81% | 1.000 |
2 | 3 | 17% | 5 | 19% |
Characteristics of target lesions in the 2 groups
LESIONS | i.v. pECT (N = 21) | i.a. pEC (N = 31) | P value | ||
---|---|---|---|---|---|
N | % | N | % | ||
Hypervascular | 2 | 9.5% | 5 | 16.1% | 0.7664 |
Intermediate | 14 | 66.7% | 20 | 64.5% | |
Hypovascular | 5 | 23.8% | 6 | 19.4% | |
Yes | 19 | 90.5% | 21 | 67.7% | 0.0927 |
No | 2 | 9.5% | 10 | 32.3% | |
Distant (> 10 mm) | 4 | 19.0% | 8 | 25.8% | 0.5389 |
Close (1 mm to 10 mm) | 6 | 28.6% | 5 | 16.1% | |
Adjacent (< 1 mm) | 11 | 52.4% | 18 | 58.1% | |
Yes | 7 | 33.3% | 8 | 25.8% | 0.7559 |
No | 14 | 66.7% | 23 | 74.2% | |
TACE (transarterial chemoembolization) | 6 | 28.6% | 4 | 12.9% | 0.1474 |
CP (chemoperfusion) | 1 | 4.8% | 0 | 0.0% | |
IBT (interstitial brachytherapy) | 0 | 0.0% | 2 | 6.5% | |
TACE/MWA/CRYOTH | 0 | 0.0% | 2 | 6.5% | |
Yes | 20 | 95.2% | 31 | 100.0% | 0.2199 |
No | 1 | 4.8% | 0 | 0.0% |